GlaxoSmithKline

March 25, 2015November 6, 2015

FDA Rejects GSK’s Breo Ellipta Asthma Therapy Use in Adolescents; Adult Use Approved

Asthma, News

The U.S. Food and Drug Administration (FDA) ruled against the use of GlaxoSmithKline‘s new drug combination Breo Ellipta in asthma patients between the ages of 12 and 17. However, the Pulmonary-Allergy Drugs Advisory Committee ... Read more

March 20, 2015November 6, 2015

FDA Analyzes Potential Limitations to GSK’s New Asthma Drug

Asthma, News

The U.S. Food and Drug Administration (FDA) recently produced a preliminary report regarding GlaxoSmithKline Plc‘s investigational combined therapy for the treatment of chronic breathing problems that revealed no additional safety issues. The medication, called Breo ... Read more

January 28, 2015November 6, 2015

GSK Expands Its COPD And Asthma Portfolio Across The US

Asthma, News

GlaxoSmithKline (GSK) recently announced that two of its latest approved products are now available in retail pharmacies across the United States to treat both chronic obstructive pulmonary disease (COPD) and asthma. In the United States over the last ... Read more

January 27, 2015November 10, 2015

GSK Reports Latest COPD International Survey Results

COPD, News

The findings from an international survey by GSK, published in The International Journal of COPD, found that, although clinicians are aware the long-term prognosis of chronic obstructive pulmonary disease (COPD) has ... Read more

November 24, 2014November 11, 2015

GSK Finishes Patient Enrollment For First “Real-World” COPD Study

COPD, News

Biopharmaceutical company GlaxoSmithKline has announced the completion of patient recruitment for their study to evaluate the effectiveness of Relvar Ellipta (fluticasone furoate “FF”/vilanterol “VI” 100/25 mcg) for the treatment of chronic obstructive pulmonary ... Read more

November 13, 2014November 11, 2015

COPD Is On The Rise In The US, According To GSK Survey

COPD, News

As World Chronic Obstructive Pulmonary Disease Day approaches on November 19, a recent GSK-led global survey is pointing to a rise of COPD in the United States. The “Continuing to ... Read more

November 7, 2014November 6, 2015

Promising News For Severe Eosinophilic Asthma Patients as GSK Submits Mepolizumab to US, European Regulators

Asthma, News

GlaxoSmithKline recently announced that the company submitted regulatory submissions, both in US and Europe, for Mepolizumab as a maintenance treatment for severe eosinophilic asthma. The news could have promising implications ... Read more

September 11, 2014November 11, 2015

New Data From GSK Shows Promising Blood Eosinophil Levels For Informing COPD Treatment Decisions

COPD, News

A team of GSK researchers recently presented at the European Respiratory Society (ERS) Congress data showing eosinophil levels in the blood may be predictors of exacerbation rates in patients with Chronic ... Read more

August 22, 2014November 6, 2015

FDA Approves GSK’s Drug Arnuity Ellipta to Treat Asthma in the US

Asthma

The U.S. Food and Drug Administration recently approved GlaxoSmithKline‘s treatment of asthma, Arnuity Ellipta (fluticasone furoate inhalation powder), as a prophylactic therapy in patients aged 12 years and older. Arnuity Ellipta is a once-daily ... Read more

August 11, 2014November 11, 2015

GlaxoSmithKline Relaunches COPD.com to Promote Education and Dialogue About the Disease

COPD, News

Pharmaceutical company GlaxoSmithKline recently launched a renewed campaign for COPD.com, a website designed to offer information, interactive, tips, helpful tools, and personal testimonials for patients suffering with chronic obstructive pulmonary disease (COPD). The ... Read more